Initial reporting of overall survival of the AHPBA pancreatic registry

Abstract

Background: Irreversible Electroporation (IRE) for locally advanced pancreatic cancer(LAPC) has been demonstrated to be safe and effective in single institutional prospective studies. They AHPBA Pancreatic Registry is the first worldwide prospective evaluation of IRE in Pancreatic Cancer. The aim of this report is to present the initial safety and efficacy of AHPBA IRE registry as part of a multimodal treatment of LAPC. Methods: From 12/2015 to 10/2017, 150 patients with radiographic stage III LAPC were treated with IRE and monitored under a multicenter, prospective IRB-approved registry. Perioperative 90- day outcomes, local failure, and overall survival were recorded. Results: 151 patients with LAPC underwent IRE of tumor (In-Situ, n = 130) or IRE with pancreatic ± arterial resection (Margin, n = 20). All patients underwent induction chemotherapy, with an additional 51% receiving chemo-radiation, for a median of 4 months (range, 3–9) p. Conclusion: This multi-national AHPBA registry further confirms the addition of IRE with established chemotherapy and/or radiation therapy can provide a significant survival advantage in LAPC.